Christoph Mann
A5010368374- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Cancer Mechanisms and Therapy
- Quinazolinone synthesis and applications
- Cancer therapeutics and mechanisms
- CAR-T cell therapy research
- Antifungal resistance and susceptibility
- Glycosylation and Glycoproteins Research
- Molecular Junctions and Nanostructures
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- MicroRNA in disease regulation
- Fungal Infections and Studies
- Medieval European History and Architecture
- Insurance, Mortality, Demography, Risk Management
- Phytochemical compounds biological activities
- Neutropenia and Cancer Infections
- HIV/AIDS drug development and treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Renal and related cancers
- Historical Influence and Diplomacy
Universitätsklinikum Gießen und Marburg
2019-2024
Philipps University of Marburg
2019-2024
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2022
The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in transplant-eligible (TE) transplant-noneligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) exclusively high-risk disease for whom prospective trials are limited, aiming to induce minimal residual (MRD) negativity.This academic, investigator-initiated, multicenter, phase II enrolled NDMM (HRNDMM) defined by mandatory International Staging System stage II/III combined...
The aim of this trial was to investigate the addition anti-SLAMF7 monoclonal antibody elotuzumab lenalidomide, bortezomib, and dexamethasone (RVd) in induction consolidation therapy as well lenalidomide maintenance treatment transplant-eligible patients with newly diagnosed multiple myeloma.
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted a significant increase minimal residual disease negativity (MRD-) rates after induction therapy. A total 662 were randomly assigned receive therapy Isa-RVd (n = 331) or RVd 329), followed by single tandem autologous stem-cell transplant and second...
With the advent of novel, highly effective therapies for multiple myeloma (MM), classical serologic monitoring appears insufficient response assessment and prediction relapse. Moreover, studies in MM are hampered by interference therapeutic antibodies. The detection malignant plasma cell clones next generation sequencing (NGS) or multiparameter flow cytometry (MFC) circumvents these difficulties can be performed peripheral blood (pB) targeting circulating cell-free DNA (cfDNA) cells (CPCs),...
8508 Background: High-risk (HR) multiple myeloma (MM) still has a significant impaired prognostic outcome. Addition of CD38 monoclonal antibodies to standard-of-care regimens significantly improved response rates and depth in newly diagnosed (ND) relapsed/refractory MM patients (pts). Here, we report the prespecified end induction interim analysis (IA) investigator-initiated GMMG-CONCEPT trial (NCT03104842), evaluating quadruplet regimen isatuximab plus carfilzomib, lenalidomide...
In the battle against multiple myeloma (MM), T cell strategies have emerged as crucial, exploiting their natural tumor-cell targeting ability to enhance patient outcomes.Recent studies underscore dual roles of cells in MM: while specific can effectively target and destroy MM cells, regulatory may block this response, highlighting complexity immune environment [1,2].Elotuzumab, SLAM family member 7 (SLAMF7) protein, represents a promising advance enhancing killer (NK) activity modulating...
<b><i>Background/Aims:</i></b> Activated fibroblasts are key controllers of extracellular matrix turnover in kidney fibrosis, the pathophysiological end stage chronic disease. The proliferation activated depends on expression calcium-dependent potassium channel KCNN4. Expression this ion is upregulated fibrotic kidneys. Genetic and pharmacological blockade KCNN4 inhibits fibrosis <i>in vitro</i> vivo</i>....
What is this summary about? This a of publication about the GMMG-CONCEPT study that was published in
Background: The multicenter phase III trial GMMG-HD7 (NCT03617731) demonstrated superior minimal residual disease (MRD) negativity rate after induction therapy in patients with transplant-eligible newly-diagnosed multiple myeloma (NDMM) by addition of the anti-CD38 monoclonal antibody isatuximab (Isa) to lenalidomide / bortezomib dexamethasone (Isa-RVd), as compared RVd alone (Goldschmidt H et al., 2021, ASH Annual Meeting). Aims: Here we present a subgroup analysis on high-risk...